丰原药业：2025年前三季度净利润同比下降31.92%

Core Insights - Fengyuan Pharmaceutical reported a revenue of 3.125 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 4.18% [1] - The net profit attributable to shareholders of the listed company was 100 million yuan, down 31.92% year-on-year [1] - Basic earnings per share decreased to 0.2158 yuan, reflecting a decline of 31.90% compared to the previous year [1]